Adverse Cardiovascular Complications following prescription of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors: a propensity-score matched Cohort Study with competing risk analysis

BACKGROUND: Programmed death-1 (PD-1) and programmed death- ligand 1 (PD-L1) inhibitors, such as pembrolizumab, nivolumab and atezolizumab, are major classes of immune checkpoint inhibitors that are increasingly used for cancer treatment. However, their use is associated with adverse cardiovascular...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Jiandong, Lee, Sharen, Lakhani, Ishan, Yang, Lei, Liu, Tong, Zhang, Yuhui, Xia, Yunlong, Wong, Wing Tak, Bao, Kelvin King Hei, Wong, Ian Chi Kei, Tse, Gary, Zhang, Qingpeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8928662/
https://www.ncbi.nlm.nih.gov/pubmed/35300724
http://dx.doi.org/10.1186/s40959-021-00128-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8928662/
https://www.ncbi.nlm.nih.gov/pubmed/35300724
http://dx.doi.org/10.1186/s40959-021-00128-5

Ejemplares similares